Review



representative tissue microarray staining  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Proteintech representative tissue microarray staining
    Fig. 9. Reduced emerin expression at the nuclear periphery correlates with breast cancer invasiveness in patients. (A) Representative tissue <t>microarray</t> staining of emerin in 159 patients using emerin polyclonal antibodies (Proteintech, cat# 10351-1-AP) or secondary alone (Vector Lab, cat#: MP-7451). Nuclei are blue, emerin is brown, and arrows denote emerin staining in certain images for reference. As severity of cases increases, there is a visible reduction in emerin expression at the nuclear envelope and more deformed nuclei are present. (B) Quantification of emerin staining on IHC-stained patient samples using 0–3, with 0 having no staining at the nuclear periphery and 3 having complete, dark rim staining. N = 159 total samples, *P < 0.05 compared to normal tissue, one-way ANOVA and Dunnett’s test. Error bars represent standard deviation. (C) Representative tissue microarray staining of emerin in 183 patients using emerin monoclonal antibodies (Leica, NCL-Emerin) or secondary alone (Vector Lab, cat#: MP-7452) using the same samples used in A. Nuclei are blue and emerin is brown. As aggressiveness of cases increases, there is a visible reduction in emerin expression and more deformed nuclei are present. (D) Quantification of emerin staining using the 0 to 3 grading system. N = 183 total samples #P < 0.02 compared to all non-cancerous tissue, *P < 0.0062 compared to both normal and benign tissue, one-way ANOVA and Dunnett’s test. Error bars represent standard deviation.
    Representative Tissue Microarray Staining, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 46 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/representative+tissue+microarray+staining/Emerin+Antibody/pm39198511-175-15-28
    Average 94 stars, based on 46 article reviews
    representative tissue microarray staining - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "Emerin deficiency drives MCF7 cells to an invasive phenotype."

    Article Title: Emerin deficiency drives MCF7 cells to an invasive phenotype.

    Journal: Scientific reports

    doi: 10.1038/s41598-024-70752-5

    Fig. 9. Reduced emerin expression at the nuclear periphery correlates with breast cancer invasiveness in patients. (A) Representative tissue microarray staining of emerin in 159 patients using emerin polyclonal antibodies (Proteintech, cat# 10351-1-AP) or secondary alone (Vector Lab, cat#: MP-7451). Nuclei are blue, emerin is brown, and arrows denote emerin staining in certain images for reference. As severity of cases increases, there is a visible reduction in emerin expression at the nuclear envelope and more deformed nuclei are present. (B) Quantification of emerin staining on IHC-stained patient samples using 0–3, with 0 having no staining at the nuclear periphery and 3 having complete, dark rim staining. N = 159 total samples, *P < 0.05 compared to normal tissue, one-way ANOVA and Dunnett’s test. Error bars represent standard deviation. (C) Representative tissue microarray staining of emerin in 183 patients using emerin monoclonal antibodies (Leica, NCL-Emerin) or secondary alone (Vector Lab, cat#: MP-7452) using the same samples used in A. Nuclei are blue and emerin is brown. As aggressiveness of cases increases, there is a visible reduction in emerin expression and more deformed nuclei are present. (D) Quantification of emerin staining using the 0 to 3 grading system. N = 183 total samples #P < 0.02 compared to all non-cancerous tissue, *P < 0.0062 compared to both normal and benign tissue, one-way ANOVA and Dunnett’s test. Error bars represent standard deviation.
    Figure Legend Snippet: Fig. 9. Reduced emerin expression at the nuclear periphery correlates with breast cancer invasiveness in patients. (A) Representative tissue microarray staining of emerin in 159 patients using emerin polyclonal antibodies (Proteintech, cat# 10351-1-AP) or secondary alone (Vector Lab, cat#: MP-7451). Nuclei are blue, emerin is brown, and arrows denote emerin staining in certain images for reference. As severity of cases increases, there is a visible reduction in emerin expression at the nuclear envelope and more deformed nuclei are present. (B) Quantification of emerin staining on IHC-stained patient samples using 0–3, with 0 having no staining at the nuclear periphery and 3 having complete, dark rim staining. N = 159 total samples, *P < 0.05 compared to normal tissue, one-way ANOVA and Dunnett’s test. Error bars represent standard deviation. (C) Representative tissue microarray staining of emerin in 183 patients using emerin monoclonal antibodies (Leica, NCL-Emerin) or secondary alone (Vector Lab, cat#: MP-7452) using the same samples used in A. Nuclei are blue and emerin is brown. As aggressiveness of cases increases, there is a visible reduction in emerin expression and more deformed nuclei are present. (D) Quantification of emerin staining using the 0 to 3 grading system. N = 183 total samples #P < 0.02 compared to all non-cancerous tissue, *P < 0.0062 compared to both normal and benign tissue, one-way ANOVA and Dunnett’s test. Error bars represent standard deviation.

    Techniques Used: Expressing, Microarray, Staining, Plasmid Preparation, Standard Deviation, Bioprocessing

    Related Articles

    Transduction:

    Article Title: Progerin-Induced Nuclear Envelope Remodeling is Shaped by Cell Division and NUP153
    Article Snippet: .. The primary antibodies and dilutions used are anti-Emerin (1:500; 10351-1-AP; Proteintech), anti-GFP (1:1000-1:2000; ab13970; abcam), anti-LaminA/C (1:200; 4777; Cell Signaling), anti-LaminB1 (1:1000; ab16048; abcam), anti-LEM2 (1:1000; 29406-1-AP; Proteintech), anti-Nesprin2 (supernatant; 10H8; a kind gift from Brian Burke), anti-Nup50 (1:500; Bethyl Laboratories), anti-Nup62 (1:200; 610497; Transduction Laboratories), anti-Nup98 (1:200; ab50610; abcam), anti-Nup153 (1:1000; ab96462; abcam), anti-Nup155 (1:500; GTX120945; Genetex), anti-SUN1 (1:250; ab124770; abcam), anti-SUN2 (supernatant; 3.1E; a kind gift from Brian Burke), and anti-tubulin alpha (1:500; MCA77G; Bio-Rad). .. The secondary antibodies used are AlexaFluor-conjugated antibodies (ThermoFisher).

    Incubation:

    Article Title: Emerin expression stratification across breast cancer subtypes.
    Article Snippet: .. Slides were then incubated with anti-emerin antibody (Proteintech, cat#: 10351–1-AP, 1:500 dilution) for two hours at 37 ◦C in a humidified chamber. .. Slides were washed again with PBS and blocked with 2.5 % Normal Goat Serum for 20 min at room temperature (ImmPRESS Reagent, Vector Lab, cat#: MP7451) and then incubated with the anti-rabbit ImmPRESS IgG peroxidase reagent (Vector Lab, cat#: MP-7451) or the anti-mouse ImmPRESS IgG peroxidase reagent (Vector Lab, cat# MP-7452) per manufacturer instructions.

    Expressing:

    Article Title: Emerin expression stratification across breast cancer subtypes.
    Article Snippet: .. We analyzed emerin expression on 86 additional patient samples by immunohistochemistry with emerin antibodies (10351–1-AP, Proteintech) on a tissue microarray (BR804b and BR480b, TissueArray, LLC) to increase the power of our studies. ..

    Immunohistochemistry:

    Article Title: Emerin expression stratification across breast cancer subtypes.
    Article Snippet: .. We analyzed emerin expression on 86 additional patient samples by immunohistochemistry with emerin antibodies (10351–1-AP, Proteintech) on a tissue microarray (BR804b and BR480b, TissueArray, LLC) to increase the power of our studies. ..

    Microarray:

    Article Title: Emerin expression stratification across breast cancer subtypes.
    Article Snippet: .. We analyzed emerin expression on 86 additional patient samples by immunohistochemistry with emerin antibodies (10351–1-AP, Proteintech) on a tissue microarray (BR804b and BR480b, TissueArray, LLC) to increase the power of our studies. ..

    Cell-Signaling:

    Article Title: Whole genome duplication through mitotic slippage causes nuclear instability.
    Article Snippet: .. Primary and secondary antibodies were used at the following concentrations: β-catenin (1/250; C2206 from Sigma-Aldrich, RRID:AB_476831), Lamin A/C (1/500; SAB4200236 from SigmaAldrich, RRID:AB_10743057), Lamin B1 (1/500; ab16048 from Abcam, RRID:AB_443298), H3S10 (1/500, 9706 from Cell Signaling, RRID:AB_331748), Lamin A/C (1:50, ADL101 from DHSB, RRID:AB_528332), Lamin B (1/50, ADL67.10 from DHSB, RRID:AB_528336), H3K9ac (1/500, 9649S from Ozyme; RRID:AB_823528), H3K14ac (1/500, ab52946 from Abcam, RRID:AB_880442); H3K27ac (1/500, 39685 from Active Motif, RRID:AB_2793305), DM1A (1/1000, T9026 from Sigma-Aldrich, RRID:AB_477593), H3K9me2 (1/500, 39239 from Active Motif, RRID:AB_2793199), H3K9me2 (1/500, ab1220 from Abcam; RRID:AB_449854), H3K9me3 (1/500, ab8898 from Abcam, RRID:AB_306848), H3K27me3 (1/500, 39155 from Active motif, RRID:AB_2561020), HP1α (1/500, ab109028 from Abcam, RRID:AB_10858495), Lap2β (1/250, 611000 from BD Bioscience, RRID:AB_398313), LBR (1/500, ab232731 from Abcam, RRID:AB_3246426), Nuclear Pore Complex (1/250, ab24609 from Abcam, RRID:AB_448181), Emerin (1/150, 10351-1-AP from ProteinTech, RRID:AB_2100056), goat anti-Rabbit IgG (H+ L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 647 (1/ 250; A21245 from ThermoFisher, RRID:AB_2535813), Goat antiRabbit IgG (H+ L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 546 (1/250; A-11035 from Thermo Fisher, RRID:AB_2534093), Goat anti-Mouse IgG1 Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (1/250, A-21121 from Thermo Fisher, RRID:AB_2535764), Goat anti-Mouse IgG2b Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (1/250, A-21141 from Thermo Fisher, RRID:AB_2535778), Goat anti-Mouse IgG2a Cross-Adsorbed Secondary Antibody, Alexa Fluor 546 (1/250, A-21133 from Thermo Fisher, RRID:AB_2535772), Alexa Fluor Plus 647 Phalloidin (1/2000, A30107 from ThermoFisher). .. To generate spheroids, 500 cells per well were seeded into 96 ultralow attachment well plates (7007 from Corning) in the presence of DMSO (276855 from Sigma- Aldrich) or with 50 μM monastrol (S8439 from Selleckchem) and 1 μM MPI-0479605 (S7488 from Selleckchem).



    Similar Products

    representative tissue microarray staining  (Proteintech)
    94
    Proteintech representative tissue microarray staining
    Fig. 9. Reduced emerin expression at the nuclear periphery correlates with breast cancer invasiveness in patients. (A) Representative tissue <t>microarray</t> staining of emerin in 159 patients using emerin polyclonal antibodies (Proteintech, cat# 10351-1-AP) or secondary alone (Vector Lab, cat#: MP-7451). Nuclei are blue, emerin is brown, and arrows denote emerin staining in certain images for reference. As severity of cases increases, there is a visible reduction in emerin expression at the nuclear envelope and more deformed nuclei are present. (B) Quantification of emerin staining on IHC-stained patient samples using 0–3, with 0 having no staining at the nuclear periphery and 3 having complete, dark rim staining. N = 159 total samples, *P < 0.05 compared to normal tissue, one-way ANOVA and Dunnett’s test. Error bars represent standard deviation. (C) Representative tissue microarray staining of emerin in 183 patients using emerin monoclonal antibodies (Leica, NCL-Emerin) or secondary alone (Vector Lab, cat#: MP-7452) using the same samples used in A. Nuclei are blue and emerin is brown. As aggressiveness of cases increases, there is a visible reduction in emerin expression and more deformed nuclei are present. (D) Quantification of emerin staining using the 0 to 3 grading system. N = 183 total samples #P < 0.02 compared to all non-cancerous tissue, *P < 0.0062 compared to both normal and benign tissue, one-way ANOVA and Dunnett’s test. Error bars represent standard deviation.
    Representative Tissue Microarray Staining, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/representative+tissue+microarray+staining/Emerin+Antibody/pm39198511-175-15-28
    Average 94 stars, based on 1 article reviews
    representative tissue microarray staining - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 9. Reduced emerin expression at the nuclear periphery correlates with breast cancer invasiveness in patients. (A) Representative tissue microarray staining of emerin in 159 patients using emerin polyclonal antibodies (Proteintech, cat# 10351-1-AP) or secondary alone (Vector Lab, cat#: MP-7451). Nuclei are blue, emerin is brown, and arrows denote emerin staining in certain images for reference. As severity of cases increases, there is a visible reduction in emerin expression at the nuclear envelope and more deformed nuclei are present. (B) Quantification of emerin staining on IHC-stained patient samples using 0–3, with 0 having no staining at the nuclear periphery and 3 having complete, dark rim staining. N = 159 total samples, *P < 0.05 compared to normal tissue, one-way ANOVA and Dunnett’s test. Error bars represent standard deviation. (C) Representative tissue microarray staining of emerin in 183 patients using emerin monoclonal antibodies (Leica, NCL-Emerin) or secondary alone (Vector Lab, cat#: MP-7452) using the same samples used in A. Nuclei are blue and emerin is brown. As aggressiveness of cases increases, there is a visible reduction in emerin expression and more deformed nuclei are present. (D) Quantification of emerin staining using the 0 to 3 grading system. N = 183 total samples #P < 0.02 compared to all non-cancerous tissue, *P < 0.0062 compared to both normal and benign tissue, one-way ANOVA and Dunnett’s test. Error bars represent standard deviation.

    Journal: Scientific reports

    Article Title: Emerin deficiency drives MCF7 cells to an invasive phenotype.

    doi: 10.1038/s41598-024-70752-5

    Figure Lengend Snippet: Fig. 9. Reduced emerin expression at the nuclear periphery correlates with breast cancer invasiveness in patients. (A) Representative tissue microarray staining of emerin in 159 patients using emerin polyclonal antibodies (Proteintech, cat# 10351-1-AP) or secondary alone (Vector Lab, cat#: MP-7451). Nuclei are blue, emerin is brown, and arrows denote emerin staining in certain images for reference. As severity of cases increases, there is a visible reduction in emerin expression at the nuclear envelope and more deformed nuclei are present. (B) Quantification of emerin staining on IHC-stained patient samples using 0–3, with 0 having no staining at the nuclear periphery and 3 having complete, dark rim staining. N = 159 total samples, *P < 0.05 compared to normal tissue, one-way ANOVA and Dunnett’s test. Error bars represent standard deviation. (C) Representative tissue microarray staining of emerin in 183 patients using emerin monoclonal antibodies (Leica, NCL-Emerin) or secondary alone (Vector Lab, cat#: MP-7452) using the same samples used in A. Nuclei are blue and emerin is brown. As aggressiveness of cases increases, there is a visible reduction in emerin expression and more deformed nuclei are present. (D) Quantification of emerin staining using the 0 to 3 grading system. N = 183 total samples #P < 0.02 compared to all non-cancerous tissue, *P < 0.0062 compared to both normal and benign tissue, one-way ANOVA and Dunnett’s test. Error bars represent standard deviation.

    Article Snippet: Reduced emerin expression at the nuclear periphery correlates with breast cancer invasiveness in patients. (A) Representative tissue microarray staining of emerin in 159 patients using emerin polyclonal antibodies (Proteintech, cat# 10351-1-AP) or secondary alone (Vector Lab, cat#: MP-7451).

    Techniques: Expressing, Microarray, Staining, Plasmid Preparation, Standard Deviation, Bioprocessing